Nat Commun:加拿大科研人员发明治疗癌症的新免疫组合疗法

2017-11-15 科技部 科技部

加拿大卡尔加里大学发布消息称,其研究人员以一种完全崭新的方法利用已经存在的治癌药物发明了一种新的免疫组合疗法,可有效治疗癌症。相关研究成果《Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms》发表在《自然通讯》(Na

加拿大卡尔加里大学发布消息称,其研究人员以一种完全崭新的方法利用已经存在的治癌药物发明了一种新的免疫组合疗法,可有效治疗癌症。相关研究成果《Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms》发表在《自然通讯》(Nature Communications)杂志上。

免疫疗法是国际抗癌斗争的一个新兴领域,科学家和临床医生几十年来一直在寻找新的方法帮助人体免疫系统发现并攻击癌细胞。癌细胞不仅知道如何躲避身体中的免疫系统,还知道如何控制特定的免疫细胞,通过改编一些免疫细胞来阻挡其它免疫细胞使其免受攻击,从而任由肿瘤自由生长。自组合化疗出现以来,旨在提高免疫系统对癌症攻击的疗法成为一种有希望的癌症治疗方法。但研究发现,单一疗法只能瞄准免疫系统的一部分,并仅对一小部分病人有效。

卡大研究人员发现,巧妙的组合疗法能够更有效的治疗癌症。胱天蛋白酶的第二线粒体活化剂-类化合物(SMCs)和溶瘤病毒(OVs)是早被研发出来的可直接杀死癌细胞的两种药物。卡大研究人员利用这两种药物的组合和相互补充,针对乳腺癌和小儿肌肉癌症,使带瘤小鼠的长期肿瘤回归比率达20%-60%。上述的SMC/OV组合疗法通过加入一种叫ɑPD-1抗体的药物进行免疫检查点封锁(ICB),形成SMC/OV/ICB三组合疗法,进而使疗效更加明显,可使带瘤小鼠的长期肿瘤消退达到将近90%。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1773060, encodeId=67ec1e7306075, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Fri Jun 29 00:10:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087203, encodeId=6bc4208e203c8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jul 13 22:10:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746058, encodeId=b7881e460588b, content=<a href='/topic/show?id=6ce1e50024b' target=_blank style='color:#2F92EE;'>#科研人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75002, encryptionId=6ce1e50024b, topicName=科研人员)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064535650230, createdName=zhangj7120, createdTime=Sat Jan 27 10:10:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882646, encodeId=e97918826467c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Aug 03 18:10:00 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312561, encodeId=6c331312561a7, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Fri Nov 17 05:10:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1773060, encodeId=67ec1e7306075, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Fri Jun 29 00:10:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087203, encodeId=6bc4208e203c8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jul 13 22:10:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746058, encodeId=b7881e460588b, content=<a href='/topic/show?id=6ce1e50024b' target=_blank style='color:#2F92EE;'>#科研人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75002, encryptionId=6ce1e50024b, topicName=科研人员)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064535650230, createdName=zhangj7120, createdTime=Sat Jan 27 10:10:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882646, encodeId=e97918826467c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Aug 03 18:10:00 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312561, encodeId=6c331312561a7, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Fri Nov 17 05:10:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
    2018-07-13 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1773060, encodeId=67ec1e7306075, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Fri Jun 29 00:10:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087203, encodeId=6bc4208e203c8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jul 13 22:10:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746058, encodeId=b7881e460588b, content=<a href='/topic/show?id=6ce1e50024b' target=_blank style='color:#2F92EE;'>#科研人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75002, encryptionId=6ce1e50024b, topicName=科研人员)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064535650230, createdName=zhangj7120, createdTime=Sat Jan 27 10:10:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882646, encodeId=e97918826467c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Aug 03 18:10:00 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312561, encodeId=6c331312561a7, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Fri Nov 17 05:10:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1773060, encodeId=67ec1e7306075, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Fri Jun 29 00:10:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087203, encodeId=6bc4208e203c8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jul 13 22:10:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746058, encodeId=b7881e460588b, content=<a href='/topic/show?id=6ce1e50024b' target=_blank style='color:#2F92EE;'>#科研人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75002, encryptionId=6ce1e50024b, topicName=科研人员)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064535650230, createdName=zhangj7120, createdTime=Sat Jan 27 10:10:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882646, encodeId=e97918826467c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Aug 03 18:10:00 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312561, encodeId=6c331312561a7, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Fri Nov 17 05:10:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
    2018-08-03 一叶知秋
  5. [GetPortalCommentsPageByObjectIdResponse(id=1773060, encodeId=67ec1e7306075, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Fri Jun 29 00:10:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087203, encodeId=6bc4208e203c8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jul 13 22:10:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746058, encodeId=b7881e460588b, content=<a href='/topic/show?id=6ce1e50024b' target=_blank style='color:#2F92EE;'>#科研人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75002, encryptionId=6ce1e50024b, topicName=科研人员)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064535650230, createdName=zhangj7120, createdTime=Sat Jan 27 10:10:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882646, encodeId=e97918826467c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Aug 03 18:10:00 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312561, encodeId=6c331312561a7, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Fri Nov 17 05:10:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]

相关资讯

肾癌的免疫组合治疗或成为治疗新标准

近期,一项来自德州大学西南医学中心的临床试验宣布,用ipilimumab(Yervoy)和nivolumab (Opdivo, 纳武单抗)两种抗体药物组合治疗肾癌,可以将癌症缓解率提高到前所未有的40%,比之前整整多了一倍!